Figure 4 — Bezafibrate mitigates cardiac injury against coronary microembolization by preventing activation of p38 MAPK/NF-κB signaling

Research Paper|Volume 16, Issue 19|pp. 12769–12780

Bezafibrate mitigates cardiac injury against coronary microembolization by preventing activation of p38 MAPK/NF-κB signaling

Back to articleFigure 4(4 of 7)

100%

Figure 4.Bezafibrate inhibited the expression of pro-inflammatory mediators TNF-α and IL-6 against CME. (A) Plasma levels of TNF-α; (B) Plasma levels of IL-6 (n=12, ^**, p<0.01 vs. control group; ^#, ^##, p<0.05, 0.01 vs. CME group).